OTS

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Retrieved on: 
Wednesday, April 3, 2024

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.

Key Points: 
  • BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.
  • “We believe 2023 was extremely productive and pivotal for TransCode.
  • The year was highlighted by preliminary clinical results from our Phase 0 clinical trial with radiolabeled TTX-MC138,” said Tom Fitzgerald, interim CEO and CFO of TransCode.
  • We also continued to achieve other important milestones, with the ultimate objective of fulfilling the promise of RNA therapeutics for oncology applications.

Bierman Autism Centers Unveils 'Adventures of Pilot the Penguin,' Educational Coloring Book, in Honor of Autism Acceptance Month

Retrieved on: 
Tuesday, April 2, 2024

This initiative highlights BAC's dedication to fostering understanding, igniting young imaginations, and actively engaging with families and communities about autism.

Key Points: 
  • This initiative highlights BAC's dedication to fostering understanding, igniting young imaginations, and actively engaging with families and communities about autism.
  • In celebration of Occupational Therapy Month, "Adventures of Pilot the Penguin" serves as a valuable resource for Occupational Therapists (OTs) at Bierman.
  • Our goal with this coloring book is to spark joy, foster educational discussions, and illuminate the incredible potential within children with autism."
  • “Adventures of Pilot the Penguin” represents more than just a coloring book; it embodies BAC's unwavering belief in the boundless potential of every child with autism.

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Retrieved on: 
Monday, March 25, 2024

Marker also executed a comprehensive non-dilutive agreement with Cell Ready which included a sale of select cell manufacturing assets from Marker for approximately $19 million in cash.

Key Points: 
  • Marker also executed a comprehensive non-dilutive agreement with Cell Ready which included a sale of select cell manufacturing assets from Marker for approximately $19 million in cash.
  • Granted ODD from the Committee for Orphan Medicinal Products of the EMA for the treatment of patients with AML in 2023.
  • On June 26, 2023, Marker completed a non-dilutive transaction with Cell Ready, under which Cell Ready purchased certain cell manufacturing assets from Marker for approximately $19 million in cash.
  • Cash Position and Guidance: At December 31, 2023, Marker had cash and cash equivalents of $15.1 million.

Accelergent Growth Solutions: Unleashing Full Potential and Accelerating Growth

Retrieved on: 
Tuesday, March 26, 2024

LITTLE ROCK, Ark., March 26, 2024 /PRNewswire/ -- DataPath, Inc. today announced the launch of Accelergent Growth Solutions to help companies in the benefits, financial services, and insurance industries accelerate their growth and profitability.

Key Points: 
  • LITTLE ROCK, Ark., March 26, 2024 /PRNewswire/ -- DataPath, Inc. today announced the launch of Accelergent Growth Solutions to help companies in the benefits, financial services, and insurance industries accelerate their growth and profitability.
  • Accelergent offers expert business process management, outsourcing, automation, and marketing services, allowing businesses to focus on core competencies and revenue-generating activities.
  • The new organization expands a 15+ year partnership between DataPath, Inc. and its sister company, Overbrook Technology Services (OTS).
  • With a 99% accuracy rate, Accelergent has processed over 3.5 million claims and numerous enrollments, plan setups, and COBRA transactions.

On The Stage Introduces Revolutionary Revenue Accelerators for Theatre Industry Amidst Transformative Shifts

Retrieved on: 
Friday, March 22, 2024

NEW YORK, March 22, 2024 /PRNewswire-PRWeb/ -- The performing arts industry stands at a critical juncture, grappling with significant shifts in patron purchasing behaviors. With many arts organizations experiencing dwindling subscription sales and renewal rates, last-minute ticket purchases on the rise, and donations decreasing, theatres face unprecedented challenges. In response, On The Stage (OTS) unveils a suite of revenue-accelerating features and workflows designed to empower organizations to navigate these challenges and ensure a prosperous future.

Key Points: 
  • NEW YORK, March 22, 2024 /PRNewswire-PRWeb/ -- The performing arts industry stands at a critical juncture, grappling with significant shifts in patron purchasing behaviors.
  • "Our latest features are a testament to our commitment to revolutionizing the theatre industry through continuous innovation," said Ryan Bush, CEO at On The Stage.
  • "We recognize the urgency for theatres to adapt to changing dynamics, and our revenue accelerators are designed to address these challenges head-on."
  • On The Stage invites theatre organizations to explore these innovative tools and resources to thrive in today's evolving landscape.

Solace Capital Partners-Backed CST Industries Acquires Ostsee Tank Solutions

Retrieved on: 
Tuesday, February 27, 2024

Solace Capital Partners, L.P. (“Solace”), a leading private equity firm focused on providing creative capital solutions for middle market companies, today announced that its portfolio company CST Industries, Inc. (“CST” or the “Company”), a global leader in storage tanks and covers, has acquired Ostsee Tank Solutions GmbH (“OTS”).

Key Points: 
  • Solace Capital Partners, L.P. (“Solace”), a leading private equity firm focused on providing creative capital solutions for middle market companies, today announced that its portfolio company CST Industries, Inc. (“CST” or the “Company”), a global leader in storage tanks and covers, has acquired Ostsee Tank Solutions GmbH (“OTS”).
  • OTS is a leading manufacturer of innovative tank solutions, including aluminum domes and covers, for various industrial applications.
  • CST plans to utilize OTS’s state-of-the-art facilities and solutions to expand production and global market usage of CST’s Optidome EUTM product line.
  • We are pleased to support the Company as it strengthens its position as a leading provider of storage tank, dome, and cover solutions,” said Christopher Brothers, Co-Founder and Managing Partner of Solace.

AFL Acquires Forza Telecom, Enhancing its Position in Wireless Markets for Major Sports Venues

Retrieved on: 
Wednesday, January 3, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240103436764/en/
    AFL Acquires Forza Telecom, Enhancing its Position in Wireless Markets for Major Sports Venues (Photo: Business Wire)
    Founded in 2010, Forza Telecom has distinguished itself as a provider of state-of-the-art DAS installations to some of the largest sports venues in North America.
  • The acquisition will strengthen AFL's U.S. Services' existing position in wireless networking for U.S. sports venues in the West and Southwest while also expanding Forza Telecom's presence in the Southeast region.
  • In addition, AFL enhances Forza Telecom's capabilities in complex RF design, large-scale installation, ongoing monitoring and maintenance services.
  • "With the addition of Forza Telecom to AFL's wireless service portfolio of Beam Wireless and Optical Telecom (OTS), AFL is elevating our position and enhancing our service offering in the DAS wireless market," explained Seneca Mullins, President of AFL's U.S. Services.

GP Strategies Joins Forces with Quantum5 to Transform Automotive Retail Industry Support

Retrieved on: 
Wednesday, January 3, 2024

COLUMBIA, Md., Jan. 3, 2024 /PRNewswire/ -- GP Strategies (GP) and Quantum5 (Q5) are joining forces to bring workforce insights and leading-edge learning solutions to OEMs and automotive retail networks in service of the modern learner and a frictionless retail experience.

Key Points: 
  • COLUMBIA, Md., Jan. 3, 2024 /PRNewswire/ -- GP Strategies (GP) and Quantum5 (Q5) are joining forces to bring workforce insights and leading-edge learning solutions to OEMs and automotive retail networks in service of the modern learner and a frictionless retail experience.
  • Automotive retail is changing rapidly, and so are learning and the learner.
  • "We think of ourselves as the Tesla of the learning industry," said Ken Herfurth, Co-Founder and Chief Vision Officer for Q5.
  • We are excited to partner with GP Strategies and to have the opportunity to level up the learning experience across automotive and other industries."

“Don’t Be the ‘I’ in DUI” Media Campaign Encourages Californians to Take Personal Responsibility in Celebrating the Holidays Safely

Retrieved on: 
Monday, December 18, 2023

The campaign focuses on how nobody wants to be the one who must explain why they drove impaired, got a DUI, and now live with the consequences.

Key Points: 
  • The campaign focuses on how nobody wants to be the one who must explain why they drove impaired, got a DUI, and now live with the consequences.
  • “Those who choose to drink and drive not only senselessly endanger themselves, but everyone else on the roadway.
  • With the holidays approaching, the CHP is intensifying enforcement efforts to quickly remove impaired drivers from our roads,” CHP Commissioner Sean Duryee said.
  • “As you celebrate and enjoy the holidays and festivities, I urge everyone to celebrate safely and never drive under the influence.

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023

HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “During the third quarter of 2023, we continued to diligently advance and execute our clinical objectives across our novel multiTAA-specific T cell pipeline,” commented Juan F. Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.
  • Third Quarter 2023 Financial Highlights:
    Cash Position: Cash and cash equivalents of $17.5 million at September 30, 2023.
  • R&D Expenses: Research and development expenses were $2.0 million for the quarter ended September 30, 2023, compared to $3.6 million for the quarter ended September 30, 2022.
  • G&A Expenses: General and administrative expenses were $1.4 million for the quarter ended September 30, 2023, compared to $3.2 million for the quarter ended September 30, 2022.